An FDA advisory panel concluded that a new drug from BioMarin Pharmaceutical hasn’t been proven to effectively treat the fatal disease called Duchenne muscular dystrophy.
WSJ.com: Health, Wall Street Journal: Business: Health
Tue, 11/24/2015 - 4:50pm
An FDA advisory panel concluded that a new drug from BioMarin Pharmaceutical hasn’t been proven to effectively treat the fatal disease called Duchenne muscular dystrophy.